EYPT Q2 2019 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+908.4% YoY

Gross Profit

$7M90.2% margin

Operating Income

-$10M-141.0% margin

Net Income

-$11M-159.5% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

+258.3%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$91M

Total Liabilities

$63M

Stockholders' Equity

$28M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$715,000	+908.4%
Gross Profit	$7M	-$4M	+260.6%
Operating Income	-$10M	-$10M	-3.9%
Net Income	-$11M	-$34M	+66.6%

Revenue Segments

Product

$7M48%

Y U T I Q Product

$7M48%

D E X Y C U Product

$684,0005%